Axovant Gene Therapies

AXGT NASDAQ
7.47
-0.13
-1.71%
After Hours: 7.42 -0.05 -0.67% 18:51 07/17 EDT
Open
7.66
Prev Close
7.60
High
7.88
Low
7.41
Volume
246.09K
Avg Vol (3M)
659.62K
52 Week High
21.28
52 Week Low
3.810
% Turnover
1.08%
Market Cap
170.17M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Axovant Gene Therapies AXGT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Axovant Gene Therapies Ltd., formerly Axovant Sciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson’s disease.
MORE >

Recently

Name
Price
%Change